Furthermore, clinical trials evaluating the efficacy of savolitinib in locally advanced or metastatic NSCLC patients with MET alterations are still ongoing (NCT04923945), also in combination with chemotherapeutic drugs (docetaxel) (NCT05777278) or immunotherapeutic agents (durvalumab) (NCT05374603). Here, MET is linked to non-small cell lung carcinoma.